Usmarapride — Safety, Research, Risks & Legal Status

Not medical advice. Usmarapride is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	SUVN-D4010
Category	Research Chemical
Drug class	Serotonin 5-HT4 receptor partial agonist
Developer	Suven Life Sciences Limited, Hyderabad, India
CAS number (free base)	1428862-32-1
Molecular formula / MW	C21H29N5O2 / 383.49 Da
Highest development stage	Phase 1 complete (NCT03031574, 2017); no Phase 2 efficacy trial published
Primary target indication	Cognitive deficits in Alzheimer's disease and schizophrenia (investigational only)
US legal status	Usmarapride is an unapproved investigational drug in the United States. It holds no FDA approval for any indication and is not commercially available. An Investigational New Drug (IND) application was submitted by Suven Life Sciences and Phase 1 trials were conducted under that authorization. It is not a dietary supplement and has no legal pathway for human consumption outside of authorized clinical trial settings.

What is Usmarapride?

Usmarapride (development code SUVN-D4010) is a small-molecule serotonin 5-HT4 receptor partial agonist under investigation by Suven Life Sciences Limited (Hyderabad, India) as a potential treatment for cognitive deficits in Alzheimer's disease and schizophrenia. Its proposed dual mechanism - cholinergic enhancement and upregulation of a neuroprotective amyloid precursor protein fragment - differentiates it mechanistically from approved Alzheimer's therapies. As of mid-2024, it has completed Phase 1 in healthy volunteers but has no published Phase 2 efficacy data in patient populations; its development status appears to be in a holding pattern.

How it works

Usmarapride acts as a partial agonist at the serotonin 5-HT4 receptor, a G-protein-coupled receptor expressed in cortical and limbic regions. Activation of this receptor in preclinical models has been associated with two downstream effects relevant to Alzheimer's pathology: (1) elevation of cortical acetylcholine levels via facilitation of cholinergic neurotransmission, addressing the cholinergic deficit characteristic of Alzheimer's disease; and (2) increased release of soluble amyloid precursor protein alpha (sAPPα), a neuroprotective fragment whose upregulation is thought to reduce amyloidogenic processing and mitigate amyloid-beta accumulation. In rodent models, usmarapride also demonstrated synergistic potentiation of donepezil (an acetylcholinesterase inhibitor), suggesting a complementary mechanism rather than overlap with existing standard-of-care agents. The compound is orally active and brain-penetrant with balanced pharmacokinetic properties per preclinical characterization.

Background & history

Usmarapride was discovered and developed by Suven Life Sciences as part of their CNS neuroscience pipeline. It was characterized under the development code SUVN-D4010 and received CAS registry numbers 1428862-32-1 (free base) and 1428862-33-2 (oxalate salt). A discovery and preclinical characterization paper was published in the Journal of Medicinal Chemistry (PMID 34251799), establishing its selectivity profile and preclinical rationale. A first-in-human Phase 1 study (NCT03031574) was completed in 2017, evaluating single-dose and multiple-dose pharmacokinetics, food effect, and age/gender effects in healthy adult and elderly volunteers. A further behavioral and neurochemical preclinical profiling study was published in Behavioural Brain Research in 2023 (PMID 36997046). Phase 2 enabling safety studies were reportedly completed, but no Phase 2b trial in Alzheimer's or schizophrenia patients has been publicly registered or reported as of the knowledge cutoff.

What the research says

Evidence base is limited to preclinical animal studies and a single completed Phase 1 pharmacokinetic/safety trial in healthy subjects. No efficacy data in human patient populations exist in the public domain. Preclinical studies in rodent models demonstrated improvements across episodic, working, social, and emotional memory paradigms, along with cortical acetylcholine elevation and increased sAPPα. The Phase 1 trial (NCT03031574, completed 2017) tested single doses up to 45 mg and multiple doses up to 40 mg daily in healthy adults and elderly subjects, finding the compound safe and generally well tolerated at those levels, with headache and nausea as the most commonly reported adverse events. Pharmacokinetic data showed lower exposure in females and elderly subjects, flagging potential need for dose adjustment in those populations. There is no published Phase 2 or Phase 3 evidence, and no efficacy signal in humans has been established. The compound should be considered early-stage investigational with an uncertain development trajectory.

Reported effects

Preclinical: elevated cortical acetylcholine in rodent models
Preclinical: increased sAPPα (neuroprotective amyloid precursor fragment) in animal studies
Preclinical: improvement across multiple rodent memory paradigms (episodic, working, social, emotional)
Preclinical: synergistic potentiation of donepezil effects in animal models
Phase 1 (human, healthy volunteers only): no major safety signals at single doses up to 45 mg and multiple doses up to 40 mg daily
No demonstrated efficacy in human patients with Alzheimer's disease or schizophrenia

Dosing & administration (informational)

The Phase 1 trial (NCT03031574) tested single oral doses up to 45 mg and multiple oral doses up to 40 mg daily in healthy adult volunteers under controlled clinical conditions. These ranges represent the only documented human exposure data and are reported here strictly for informational context. They do not constitute dosing guidance, a protocol, or a therapeutic recommendation of any kind. No therapeutic dose for any indication has been established, as no Phase 2 efficacy trial has been completed. Anyone considering participation in a legitimate clinical trial should consult the relevant investigators and their own clinician.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

Phase 1 data (healthy volunteers only): generally safe and well tolerated at doses tested
Most common adverse events in Phase 1: headache and nausea, described as predominantly mild
No major safety signals reported in Phase 1 or Phase 2 enabling studies per Suven disclosures
Lower drug exposure observed in females and elderly subjects; clinical implications unknown without efficacy trials
Long-term safety is unknown - no chronic dosing data in humans has been published
No safety data exists in patient populations (Alzheimer's or schizophrenia patients)
Not approved for human use; no self-administration context exists with any regulatory sanction

Drug & supplement interactions

N
o
s
y
s
t
e
m
a
t
i
c
d
r
u
g
i
n
t
e
r
a
c
t
i
o
n
s
t
u
d
i
e
s
i
n
h
u
m
a
n
s
h
a
v
e
b
e
e
n
p
u
b
l
i
s
h
e
d
.
P
r
e
c
l
i
n
i
c
a
l
d
a
t
a
s
u
g
g
e
s
t
a
d
d
i
t
i
v
e
o
r
s
y
n
e
r
g
i
s
t
i
c
e
f
f
e
c
t
s
w
i
t
h
d
o
n
e
p
e
z
i
l
(
a
n
a
c
e
t
y
l
c
h
o
l
i
n
e
s
t
e
r
a
s
e
i
n
h
i
b
i
t
o
r
)
,
w
h
i
c
h
c
o
u
l
d
t
h
e
o
r
e
t
i
c
a
l
l
y
a
m
p
l
i
f
y
c
h
o
l
i
n
e
r
g
i
c
e
f
f
e
c
t
s
a
n
d
a
s
s
o
c
i
a
t
e
d
a
d
v
e
r
s
e
e
v
e
n
t
s
.
G
i
v
e
n
i
t
s
s
e
r
o
t
o
n
e
r
g
i
c
m
e
c
h
a
n
i
s
m
(
5
-
H
T
4
p
a
r
t
i
a
l
a
g
o
n
i
s
m
)
,
i
n
t
e
r
a
c
t
i
o
n
s
w
i
t
h
o
t
h
e
r
s
e
r
o
t
o
n
e
r
g
i
c
a
g
e
n
t
s
a
r
e
a
t
h
e
o
r
e
t
i
c
a
l
c
o
n
c
e
r
n
b
u
t
h
a
v
e
n
o
t
b
e
e
n
c
h
a
r
a
c
t
e
r
i
z
e
d
i
n
h
u
m
a
n
s
.
N
o
i
n
t
e
r
a
c
t
i
o
n
d
a
t
a
w
i
t
h
C
Y
P
e
n
z
y
m
e
s
,
t
r
a
n
s
p
o
r
t
e
r
s
,
o
r
c
o
m
m
o
n
l
y
c
o
-
p
r
e
s
c
r
i
b
e
d
m
e
d
i
c
a
t
i
o
n
s
i
n
t
h
e
A
l
z
h
e
i
m
e
r
'
s
p
o
p
u
l
a
t
i
o
n
h
a
v
e
b
e
e
n
d
i
s
c
l
o
s
e
d
i
n
t
h
e
p
u
b
l
i
c
d
o
m
a
i
n
.

Who should avoid it

Concurrent use with other serotonergic agents (theoretical interaction risk, uncharacterized in humans)
Use outside of authorized clinical trial settings - no approved indication exists
Self-administration - no safe or effective dose for any condition has been established in humans
Use by individuals with cardiac arrhythmias - 5-HT4 receptor agonists as a class have historically raised QT/proarrhythmic questions, though no specific signal was reported for usmarapride in Phase 1

How it is commonly combined

No stacking data exists in humans. Preclinical experiments combined usmarapride with donepezil and observed potentiated effects, but the clinical relevance, safety margin, and appropriate ratios for any such combination are entirely unknown. No evidence base supports combining usmarapride with any other compound outside of a controlled trial.

Legal & regulatory. Usmarapride is an unapproved investigational drug in the United States. It holds no FDA approval for any indication and is not commercially available. An Investigational New Drug (IND) application was submitted by Suven Life Sciences and Phase 1 trials were conducted under that authorization. It is not a dietary supplement and has no legal pathway for human consumption outside of authorized clinical trial settings.

Quality & harm reduction

Safer, legal alternative we recommend

Brainy Bunch Formula. For the same cognitive-support goal, our Brain & Focus Formula is a legal nootropic blend you can buy today.

See our recommended pick

Find Usmarapride →

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

Has usmarapride been shown to work in Alzheimer's patients?

No. All efficacy data to date come from rodent models. The Phase 1 trial enrolled healthy volunteers and elderly subjects to assess pharmacokinetics and tolerability, not cognitive efficacy. No Phase 2 trial in Alzheimer's or schizophrenia patients has been completed or published. Preclinical results cannot be directly extrapolated to human efficacy.

What dose should I take?

This is not a question that can be answered here, and no responsible answer exists outside of a clinical trial context. Usmarapride is an unapproved investigational compound with no established therapeutic dose for any condition. The Phase 1 ranges are reported in the literature for informational context only. Anyone seeking treatment for cognitive decline should consult a licensed clinician and explore approved therapies or enrolling in legitimate clinical research.

Is usmarapride available to buy?

It is not commercially available through any legitimate channel. It was synthesized for controlled preclinical research and Phase 1 trials under IND authorization. Any material sold outside of authorized research settings has no verified identity, purity, or safety profile.

What is the current development status?

As of mid-2024, Phase 1 is complete and Phase 2 enabling safety studies were reportedly finished, but no Phase 2 efficacy trial in patients has been publicly registered or reported. Development appears stalled or deprioritized; Suven Life Sciences has not made recent public announcements about advancing the compound. Its pipeline status is uncertain.

How does usmarapride differ from existing Alzheimer's drugs?

Approved acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) increase synaptic acetylcholine by blocking its breakdown. Usmarapride is proposed to act upstream via 5-HT4 receptor agonism to stimulate acetylcholine release and additionally upregulate sAPPα, a neuroprotective amyloid precursor fragment thought to reduce amyloidogenic processing. This dual mechanism is pharmacologically distinct, though whether it translates to clinical benefit remains undemonstrated.

Are there safety concerns with 5-HT4 agonists as a class?

Historically, some 5-HT4 agonists (e.g., cisapride, tegaserod) raised cardiovascular safety concerns related to QT prolongation and arrhythmias, which contributed to regulatory withdrawals or restrictions. Usmarapride's Phase 1 did not report major cardiac safety signals at doses tested, but long-term cardiovascular data in patient populations do not exist. This class-level concern is a reason why thorough Phase 2 evaluation in target populations would be necessary before any conclusions about clinical safety can be drawn.

References & further reading

PubMed: usmarapride SUVN-D4010 5-HT4 receptor partial agonist discovery preclinical characterization Journal of Medicinal Chemistry (PMID 34251799)
PubMed: usmarapride SUVN-D4010 Alzheimer's disease behavioural neurochemical pharmacological profiling Behavioural Brain Research 2023 (PMID 36997046)
PubMed: usmarapride SUVN-D4010 first-in-human safety tolerability pharmacokinetics Clinical Drug Investigation (PMID 33787223)
ClinicalTrials.gov: NCT03031574 SUVN-D4010 Phase 1 pharmacokinetics healthy volunteers elderly